Qingzhu Jia1, Yi Yang1, Ying Wan1. 1. Biomedical Analysis Center, Third Military Medical University Chongqing, China ; Chongqing Key Laboratory of Cytomics Chongqing, China.
Abstract
PURPOSE: Pathological evidence has continually supported the prognostic value of tumour-infiltrating T lymphocytes for several solid tumours across diverse patient cohorts. To investigate the clinical relevance of tumour-infiltrating memory T lymphocytes, we investigated relevant publications to identify the significance of memory tumour-infiltrating T lymphocytes (TILs) in predicting survival in cancer patients and analysed the influence of variations in the tumour stage and the infiltrated location thereon. METHODS: Relevant publications that assessed the clinical relevance of memory TILs to the patient's overall survival (OS) were investigated. Disease-free survival (DFS) was also evaluated where possible. Hazard ratios (HR) and 95% confidence intervals (CI) were assessed using a random-effects model. Heterogeneity was investigated with stratified analysis and I(2) statistics. RESULTS: In total, 16 relevant publications, including 4248 cancer patients, were analysed. In the pooled analysis, intra-tumour accumulation of memory TILs correlated positively with favourable clinical outcomes for both OS (pooled HR, 2.06; 95% CI, 1.76-2.40) and DFS (pooled HR, 2.31; 95% CI, 1.67-3.19). Various effects of the tumour stage and the anatomical region where the cells infiltrated were identified in survival prediction, using memory TILs. CONCLUSIONS: Overall, infiltration of memory TILs can serve as a biomarker for survival prediction in cancer. Additional heterogeneous effects of the associated factors should be considered when categorizing high-risk patients.
PURPOSE: Pathological evidence has continually supported the prognostic value of tumour-infiltrating T lymphocytes for several solid tumours across diverse patient cohorts. To investigate the clinical relevance of tumour-infiltrating memory T lymphocytes, we investigated relevant publications to identify the significance of memory tumour-infiltrating T lymphocytes (TILs) in predicting survival in cancerpatients and analysed the influence of variations in the tumour stage and the infiltrated location thereon. METHODS: Relevant publications that assessed the clinical relevance of memory TILs to the patient's overall survival (OS) were investigated. Disease-free survival (DFS) was also evaluated where possible. Hazard ratios (HR) and 95% confidence intervals (CI) were assessed using a random-effects model. Heterogeneity was investigated with stratified analysis and I(2) statistics. RESULTS: In total, 16 relevant publications, including 4248 cancerpatients, were analysed. In the pooled analysis, intra-tumour accumulation of memory TILs correlated positively with favourable clinical outcomes for both OS (pooled HR, 2.06; 95% CI, 1.76-2.40) and DFS (pooled HR, 2.31; 95% CI, 1.67-3.19). Various effects of the tumour stage and the anatomical region where the cells infiltrated were identified in survival prediction, using memory TILs. CONCLUSIONS: Overall, infiltration of memory TILs can serve as a biomarker for survival prediction in cancer. Additional heterogeneous effects of the associated factors should be considered when categorizing high-risk patients.
Entities:
Keywords:
Cancer; memory T cells; prognosis; survival; tumour-infiltrating lymphocyte
Authors: David Masopust; Daniel Choo; Vaiva Vezys; E John Wherry; Jaikumar Duraiswamy; Rama Akondy; Jun Wang; Kerry A Casey; Daniel L Barber; Kim S Kawamura; Kathryn A Fraser; Richard J Webby; Volker Brinkmann; Eugene C Butcher; Kenneth A Newell; Rafi Ahmed Journal: J Exp Med Date: 2010-02-15 Impact factor: 14.307
Authors: E Halapi; Y Yamamoto; C Juhlin; M Jeddi-Tehrani; J Grunewald; R Andersson; C Hising; G Masucci; H Mellstedt; R Kiessling Journal: Cancer Immunol Immunother Date: 1993 Impact factor: 6.968
Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: R A de Jong; N Leffers; H M Boezen; K A ten Hoor; A G J van der Zee; H Hollema; H W Nijman Journal: Gynecol Oncol Date: 2009-05-02 Impact factor: 5.482
Authors: Daniel J Munson; Colt A Egelston; Kami E Chiotti; Zuly E Parra; Tullia C Bruno; Brandon L Moore; Taizo A Nakano; Diana L Simons; Grecia Jimenez; John H Yim; Dmitri V Rozanov; Michael T Falta; Andrew P Fontenot; Paul R Reynolds; Sonia M Leach; Virginia F Borges; John W Kappler; Paul T Spellman; Peter P Lee; Jill E Slansky Journal: Proc Natl Acad Sci U S A Date: 2016-06-15 Impact factor: 11.205
Authors: Sita S Withers; Katherine A Skorupski; Daniel York; Jin W Choi; Kevin D Woolard; Renee Laufer-Amorim; Ellen E Sparger; Carlos O Rodriguez; Stephen J McSorley; Arta M Monjazeb; William J Murphy; Robert J Canter; Robert B Rebhun Journal: Vet Comp Oncol Date: 2018-09-19 Impact factor: 2.613
Authors: Andressa S Laino; B C Betts; A Veerapathran; I Dolgalev; A Sarnaik; S N Quayle; S S Jones; J S Weber; David M Woods Journal: J Immunother Cancer Date: 2019-02-06 Impact factor: 13.751
Authors: Jennifer L Hope; Christopher J Stairiker; Eun-Ah Bae; Dennis C Otero; Linda M Bradley Journal: Front Immunol Date: 2019-07-17 Impact factor: 7.561